ABSTRACT BACKGROUND: Stroke is a major cause of morbidity and mortality. We describe trends in the incidence, outcomes, and risk factors for stroke in the US Medicare population from 1988 to 2008.
for policy purposes, including describing the past and current scope of the condition, assessing the potential effect of strokeprevention interventions on a national level, and identifying areas where resources can be targeted more specifically and effectively. The primary objective of this analysis was to examine 2 decade-long trends from 1988 to 2008 in the incidence of, and subsequent short-term mortality from, stroke among individuals aged 65 years in the United States. We then assessed factors that could explain changes in the incidence of ischemic stroke, the highest burden subtype among elderly persons in the United States. We focused on trends in clinical risk factors for stroke and trends in the uptake of medications that attenuate stroke risk. Rates and outcomes of stroke were determined separately for men and women because of increasing evidence that there are sex-related differences in stroke incidence, risk factors, treatment, and outcomes.
METHODS Data Sources, Stroke Incidence, and Mortality
We used a 20% sample of Medicare Provider Analysis and Review data to identify fee-for-service Medicare beneficiaries aged 65 years hospitalized for stroke between 1988 and 2008. Stroke hospitalizations were identified as principal discharge diagnoses of International Classification of Diseases, Ninth Revision, Clinical Modification codes of 434.x and 436.x for ischemic stroke and 430.x and 431.x for hemorrhagic stroke. Our study addressed only the first hospitalization for stroke for each individual during the time period, which was considered the index event. Although these methods assume that the stroke event was incident, we lacked information about potential stroke events that may have occurred at ages less than 65 years. We also searched for principal discharge diagnosis of transient ischemic attack (International Classification of Diseases, Ninth Revision, Clinical Modification code 435.x) because advances in imaging techniques may have resulted in increasing numbers of transient ischemic attacks being coded as acute ischemic strokes over time.
Medicare denominator files were used to ascertain beneficiaries' date of birth, sex, race (categorized as black, white, or other), enrollment status, region of residence (Midwest, Northeast, South, or West), and vital status (including date of death). We excluded patients residing outside the United States (n ¼ 11,668, 1%) and patients enrolled in a Medicare health maintenance organization during the study period (n ¼ 146,493, 14%), because Medicare Provider Analysis and Review data may not capture complete health care claims data for these individuals.
Information on clinical comorbidities was obtained using a 2-year look-back window from the index admission date, excluding diagnoses obtained solely from the index admission. The comorbidities included in the Klabunde adaptation of the Charlson comorbidity index were used for risk adjustment.
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Risk Factors and Preventive Medications
To examine possible explanations for reductions in stroke incidence, we calculated the predicted risk of stroke at 3 different time intervals using the Framingham stroke risk index, a validated instrument developed in the Framingham Heart Study cohort. 7 We obtained data on the prevalence and physiologic level of stroke risk factors among patients from the Third National Health and Nutrition Examination Survey (NHANES III) aged 65 years or older with Medicare coverage using surveys conducted from 1988 to 1994, as well as from the continuous NHANES survey data from 2001 to 2008. The NHANES is a nationally representative survey of the civilian, noninstitutionalized population, which collects detailed data on medical conditions through direct patient interview and physiologic measurements through a mobile examination component. 8 The prevalence of specific risk factors for stroke included self-reported coronary heart disease, congestive heart failure, diabetes, vascular disease, and hyperlipidemia. In addition, we obtained data on measured blood pressure, body mass index, total cholesterol, low-density lipoprotein cholesterol levels, and self-reported smoking status.
A number of medications have been shown to prevent strokes and to reduce the severity of strokes that do occur, including statins, antihypertensive agents, and antiplatelet medications. 1, 9 We obtained rates of use of these medications among the Medicare population aged 65 years using the 1992-2008 Medicare Current Beneficiary Survey (MCBS). The MCBS is conducted on a representative sample of Medicare beneficiaries drawn from Medicare enrollment databases.
10 Community-dwelling adults provide self-reported information on medication use, which is complemented with benefit statements, pharmacy receipts, and medication containers provided to the interviewers 3 times yearly, as well as Medicare Part D prescription databases for [2006] [2007] [2008] (clopidogrel and ticlopidine). Use of aspirin, because it is available without prescription, was not completely captured by the MCBS and was not included in the analysis.
Outcome Measures
Primary outcomes included stroke incidence and 30-day mortality, stratified by stroke subtype (ischemic vs hemorrhagic). Secondary outcomes included predicted stroke risk applying the Framingham risk equation to NHANES risk factors and rates of medication use from MCBS.
Data Analysis
Annual rates of hospitalization for first stroke were calculated for ischemic and hemorrhagic strokes among feefor-service Medicare beneficiaries aged 65 years and reported as number of events per 100,000 beneficiaries. Rates were standardized to the age and sex distribution of the year 2000 population, and trends in the risk of stroke as a function of year were assessed using logistic regression, controlling for age. Changes in the demographic and clinical characteristics of stroke patients from 1988 to 2008 were examined separately for ischemic and hemorrhagic strokes. Analysis of variance was used for comparison of continuous variables and chi-square tests for categoric variables.
Sex-specific mortality rates were ascertained at 30 days after the index stroke admission and are reported separately for ischemic and hemorrhagic strokes. Risk adjusted 30-day mortality rates were calculated using logistic regression, controlling for age, sex (except for sex-stratified analyses), race, region, and medical comorbidities.
We calculated a mean Framingham stroke risk score for NHANES respondents aged 65 years with Medicare coverage at 3 time intervals : 1988-1994, 2001-2004, and 2005-2008 . The Framingham stroke risk score incorporates specific clinical risk factors (age, systolic blood pressure, antihypertensive treatment, diabetes mellitus, smoking status, cardiovascular disease, atrial fibrillation, and left ventricular hypertrophy) to calculate a 10-year risk of stroke. 7 Electrocardiographic data on left ventricular hypertrophy were available only for NHANES participants in years 1988-1994, so for subsequent years, left ventricular hypertrophy prevalence was estimated using data from the medical literature. 11 Likewise, atrial fibrillation prevalence was obtained from a population-based study reporting atrial fibrillation rates for the years 1992 to 2002. 12 The prevalence of atrial fibrillation for earlier and later years was imputed assuming a linear trend, and we also ran the analysis assuming no change in atrial fibrillation rates. The 10-year Framingham stroke risk score was calculated for each individual in the NHANES, and risks were then averaged over each time interval and reported as mean and standard deviation for each of the 3 time periods.
Finally, we tested for changes in the self-reported use of specific classes of medications used to prevent stroke using data from the MCBS. Rates were calculated as the proportion of MCBS participants reporting use of specific medications divided by the total number of MCBS participants in that given year. Linear regression was used to test for changes in the rate of use by year.
Analyses were performed using the SAS 9.2 statistical package (SAS Institute Inc, Cary, NC). Risk factor and medication trend analyses took into account the complex survey sample design of both the NHANES and MCBS surveys. Significance was set at P < .05 using 2-sided tests for all analyses. This study was approved by the institutional review board of the University of California, San Francisco.
RESULTS
Trends in Stroke Incidence
We identified 1,051,342 incident strokes from 1988 to 2008 (representing 20% of Medicare claims), of which 918,124 (87.3%) were ischemic and 133,218 (12.7%) were hemorrhagic strokes. Patients presenting with stroke frequently had concomitant risk factors, the most prevalent being hypertension, diabetes, and hyperlipidemia (Tables 1 and 2). A prior diagnosis of transient ischemic attack at age 65 years was observed among 64,749 patients (7.1%) with ischemic stroke and 6261 patients (4.7%) with hemorrhagic stroke.
The incidence of first stroke decreased significantly over time, from an age-adjusted rate of 1039 per 100,000 (95% confidence interval [CI], 1032-1045) in 1988 to 639 per 100,000 (95% CI, 634-644) in 2008. The decline was largely due to a marked reduction in the rate of ischemic stroke, which decreased overall from 927 per 100,000 (95% CI, 923-931) in 1988 to 545 per 100,000 (95% CI, 542-548) in 2008 (P < .001). In men, the rates were 955 per 100,000 (95% CI, 948-962) and 505 per 100,000 (95% CI, 500-509); in women, the rates were 908 per 100,000 (95% CI, 902-913) and 572 per 100,000 (95% CI, 568-577) (P values < .001) (Figure 1) .
Rates of hemorrhagic stroke did not show as great a decline as ischemic stroke, decreasing from 112 per 100,000 
Trends in Stroke Mortality
Crude 30-day mortality from ischemic stroke decreased from 16 (P < .001). The 30-day mortality from ischemic stroke decreased from 16.3% to 11.2% in men and from 15.6% to 13.6% in women (P < .001 for both, Figure 2 ). Thirty-day mortality from hemorrhagic stroke also decreased over time, albeit less so than ischemic stroke: Crude mortality rates decreased from 43.4% in 1988 to 42.1% in 2008 and risk-adjusted from 44.7% to 39.3% (P < .001 for both, Figure 2) . The 30-day mortality from hemorrhagic stroke decreased from 45.2% to 38.8% among men and from 44.4% to 39.6% among women (P < .001 for both, Figure 2 ). Figure 3 shows trends in the use of antihypertensives, statins, and non-aspirin antiplatelet agents by Medicare beneficiaries aged 65 years or more. Antihypertensive medication use increased significantly from 1992 to 2008, as did statin use (P < .001 for both), which showed a marked increase particularly after 1996. We also observed increased prescription antiplatelet medication use over the time period, but the overall prevalence of antiplatelet use in the population was low.
Trends in Risk Factors and Predicted Incidence of Stroke
Trends in Medication Use
DISCUSSION
The rate of first stroke among patients aged 65 years decreased by approximately 40% over the last 2 decades in the US Medicare population, a decline driven primarily by marked reductions in the incidence of ischemic stroke. Hemorrhagic stroke rates showed a smaller decline, primarily among men. Short-term mortality from both ischemic and hemorrhagic strokes also declined over time, although hemorrhagic strokes continue to be associated with poor outcomes. The large decline in stroke rates was not matched by concomitant reductions in stroke risk factors that were part of the Framingham stroke risk score, but did parallel a substantial increase in the use of antihypertensive medications and statins in the general Medicare population. Our study confirms earlier reports of declining stroke rates and was able to compare how the prevalence of stroke risk factors tracked with actual observed rates in stroke. [13] [14] [15] [16] [17] Figure 1 Age-adjusted incidence of ischemic and hemorrhagic stroke in the US Medicare population from 1988 to 2008. Figure 2 Risk-adjusted 30-day mortality rates after hospitalization for ischemic or hemorrhagic stroke from 1988 to 2008 in a 20% sample of Medicare patients, adjusted for age, region, race, acute/prior myocardial infarction, congestive heart failure, vascular disease, pulmonary disease, dementia, paralysis, diabetes, renal disease, liver disease, ulcer disease, rheumatologic disease, and cancer.
Although some risk factors for stroke declined over time, such as reductions in rates of smoking, total cholesterol level, and systolic blood pressure, the magnitude of the observed reductions in stroke rate was greater than what might be estimated by the Framingham stroke score. It is possible that the Framingham stroke risk score does not validate well in our population. The increase in mean Framingham risk score in our study was primarily driven by an increase in the rates of diagnosed diabetes mellitus and the increased prevalence of antihypertensive medication use. Because criteria for diabetes mellitus diagnosis have changed over time, as have goal blood pressure targets, the calculated stroke risk score may not accurately reflect differences in actual stroke risk. The effect of risk factor changes also may not be detectable in the short-term. The Framingham model was developed in a cohort of welleducated, middle-class individuals of predominantly European descent and may not reflect the baseline cardiovascular risk and racial/ethnic composition of the Medicare population we studied.
It also is possible that improved risk factor modification, such as more stringent blood pressure control and administration of statins, has significantly decreased the population stroke rate. Although our study design precludes us from making causal explanations, the decline in stroke rates occurred over a period of significant uptake in the use of medications that attenuate stroke risk. Antihypertensive medications reduce the risk of stroke by approximately 32%, and statins reduce the risk of stroke by approximately 21%. 1, 3, 4 Stroke rates seem to decrease most sharply after year 1998, approximately when statin use became more prevalent. Use of prescription antiplatelet agents increased over the time period, but these agents were unlikely to be a major contributing factor to the reduction in stroke rates because of the weak effects of antiplatelets on primary stroke prevention and the low prevalence of use in our study.
Short-term stroke-related mortality from stroke has decreased significantly over time. Our analysis confirms the continuing and devastating effect of hemorrhagic stroke. Our analysis was unable to assess for causal factors influencing mortality rates; relatively few interventions have been shown to reduce stroke-related mortality. Timely administration of intravenous thrombolytics is associated with more favorable outcomes from ischemic stroke, but has not been shown to have significant effects on mortality. 9 In addition, the rate of thrombolytic administration continues to be low in the United States. 18 
Study Limitations
Our report focuses on the US population aged 65 years and so is unable to assess trends in stroke rates and case fatality in younger individuals. In addition, although it was likely that the majority of strokes were incident events, it is possible that some subjects had stroke events at ages <65 years that could not be captured by the Medicare database. Thus, our study can only comment on stroke rates occurring at ages 65 years and older. Stroke events were identified using administrative data, which are subject to misclassification and imperfect sensitivity and specificity. However, we note that the primary objective was to describe relative rather than absolute changes in incidence and mortality over time. We were not able to determine causality between medication use and stroke rates and outcomes, and we lacked accurate assessments of nonprescription medications, in particular, aspirin. Although aspirin does not seem to have strong effects in the primary prevention of ischemic stroke, it may have small effects on reducing the risk of incident stroke in women. 1 We obtained data from several databases that had different means of data collection and ascertainment of risk factors. Unmeasured or unknown factors other than the risk factors and medications we examined in the analyses may have contributed to the observed reduction in stroke rate. In addition, we were not able to ascertain whether the medications studied were specifically used for stroke risk reduction or for the secondary prevention of stroke. Atrial fibrillation and left ventricular hypertrophy were extrapolated from national estimates, although our findings did not change when we assumed that the prevalence of atrial fibrillation was unchanged over the time period. Because the actual prevalence of atrial fibrillation seems to be increasing over time, it is unlikely that the observed declines in stroke rates were due to the decreased population prevalence of atrial fibrillation.
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CONCLUSIONS
The rates of incident stroke have significantly decreased over the last 20 years in the US Medicare population, as has shortterm stroke mortality. Antihypertensive medications and statin use increased significantly over the time period and might explain the observed decline in stroke rates. If true, then this illustrates how medical interventions have resulted in significant improvements in health on a population level.
